IS6957A - Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9,-pentaen og lyfjafræðilegar samsetningar af þeim - Google Patents

Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9,-pentaen og lyfjafræðilegar samsetningar af þeim

Info

Publication number: IS6957A
Authority: IS; Iceland
Prior art keywords: triacetetracyclo; tatrate; pentaene; hexadecene; salts
Prior art date: 2001-05-14

Application number

IS6957A

Other languages

English (en)

Other versions

IS2217B (is

Inventor

Everett Bogle David

Robert Rose Peter

Robert Williams Glenn

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-14

Filing date

2003-09-15

Publication date

2003-09-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS6957(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-09-15 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2003-09-15 Publication of IS6957A publication Critical patent/IS6957A/is

2007-03-15 Publication of IS2217B publication Critical patent/IS2217B/is

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Addiction (AREA)
Diabetes (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Hematology (AREA)
Psychology (AREA)
Nutrition Science (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Endocrinology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Rheumatology (AREA)
Tropical Medicine & Parasitology (AREA)
Orthopedic Medicine & Surgery (AREA)

IS6957A 2001-05-14 2003-09-15 Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,8,-pentaeni. IS2217B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29086101P	2001-05-14	2001-05-14
PCT/IB2002/001437 WO2002092089A1 (en)	2001-05-14	2002-04-26	Tartrate salts of 5,8,14-triazatetracyclo {10.3.1.0?2,11.04,9¿}-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Publications (2)

Publication Number	Publication Date
IS6957A true IS6957A (is)	2003-09-15
IS2217B IS2217B (is)	2007-03-15

Family

ID=23117845

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS6957A IS2217B (is)	2001-05-14	2003-09-15	Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,8,-pentaeni.

Country Status (48)

Country	Link
US (2)	US6890927B2 (is)
EP (1)	EP1392307B1 (is)
JP (1)	JP3779682B2 (is)
KR (1)	KR100551184B1 (is)
CN (1)	CN100370987C (is)
AP (1)	AP1473A (is)
AR (1)	AR033635A1 (is)
AT (1)	ATE302607T1 (is)
AU (1)	AU2002253482B2 (is)
BG (1)	BG66408B1 (is)
BR (1)	BR0209605A (is)
CA (1)	CA2447405C (is)
CR (1)	CR7080A (is)
CZ (1)	CZ304763B6 (is)
DE (1)	DE60205742T2 (is)
DK (1)	DK1392307T3 (is)
DO (1)	DOP2002000392A (is)
EA (1)	EA005528B1 (is)
EC (2)	ECSP034849A (is)
EE (1)	EE05441B1 (is)
EG (1)	EG24228A (is)
ES (1)	ES2246396T3 (is)
GE (1)	GEP20053712B (is)
GT (1)	GT200200084A (is)
HK (1)	HK1062645A1 (is)
HR (1)	HRP20030910B1 (is)
HU (1)	HU229867B1 (is)
IL (2)	IL157933A0 (is)
IS (1)	IS2217B (is)
MA (1)	MA27020A1 (is)
ME (1)	ME00466B (is)
MX (1)	MXPA03010364A (is)
MY (1)	MY127807A (is)
NO (1)	NO326148B1 (is)
NZ (1)	NZ528210A (is)
OA (1)	OA12599A (is)
PA (1)	PA8545101A1 (is)
PE (1)	PE20021065A1 (is)
PL (1)	PL214876B1 (is)
PT (1)	PT1392307E (is)
RS (1)	RS50814B (is)
SI (1)	SI1392307T1 (is)
SK (1)	SK287170B6 (is)
TN (1)	TNSN03113A1 (is)
TW (1)	TWI262078B (is)
UA (1)	UA73422C2 (is)
WO (1)	WO2002092089A1 (is)
ZA (1)	ZA200307235B (is)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ504482A (en) *	1997-12-31	2003-01-31	Pfizer Prod Inc	Aryl fused azapolycyclic compounds and pharmaceuticals thereof which bind to neuronal nicotinic acetylcholine specific recpetor sites and are useful for modulating cholinergic function
EP1448235B1 (en) *	2001-11-30	2007-03-14	Pfizer Products Inc.	Oral controlled release pharmaceutical compositions of 5,8,14-triazatetracyclo 10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
MXPA05012507A (es) *	2003-05-20	2006-01-30	Pfizer Prod Inc	Composiciones farmaceuticas de vareniclina.
JP2007514759A (ja) *	2003-12-19	2007-06-07	タケダサンディエゴインコーポレイテッド	キナーゼ阻害剤
US20050250829A1 (en) *	2004-04-23	2005-11-10	Takeda San Diego, Inc.	Kinase inhibitors
EA010307B1 (ru) *	2004-06-30	2008-08-29	Эли Лилли Энд Компани	Фармацевтическое соединение
US7550598B2 (en) *	2004-08-18	2009-06-23	Takeda Pharmaceutical Company Limited	Kinase inhibitors
WO2006040680A1 (en) *	2004-10-15	2006-04-20	Pfizer Products Inc.	Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
WO2006044687A2 (en) *	2004-10-15	2006-04-27	Takeda San Diego, Inc.	Kinase inhibitors
AU2006217616A1 (en) *	2005-02-24	2006-08-31	Pfizer Products Inc.	Preparation of high purity substituted quinoxaline
US20110086086A1 (en) *	2005-07-26	2011-04-14	Pfizer Inc	Transdermal system for varenicline
US8119655B2 (en) *	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
US20070293702A1 (en) *	2006-02-21	2007-12-20	Viviana Braude	Novel crystalline forms of armodafinil and preparation thereof
JP2010505961A (ja) *	2006-10-09	2010-02-25	タケダサンディエゴインコーポレイテッド	キナーゼ阻害剤
GEP20135728B (en)	2006-10-09	2013-01-25	Takeda Pharmaceuticals Co	Kinase inhibitors
AU2007319951A1 (en) *	2006-11-09	2008-05-22	Pfizer Products Inc.	Polymorphs of nicotinic intermediates
US20090062257A1 (en) *	2007-08-29	2009-03-05	Protia, Llc	Deuterium-enriched varenicline
US20090105346A1 (en) *	2007-10-02	2009-04-23	Alexandr Jegorov	Novel crystalline forms of armodafinil and preparation thereof
US20090215787A1 (en) *	2008-02-22	2009-08-27	Mai De Ltd.	Preparations of new polymorphic forms of varenicline tartrate
EP2262780A4 (en) *	2008-03-06	2012-01-25	Reddys Lab Ltd Dr	TARTRATE OF VARENICLINE AMORPHOUS
US8440825B2 (en)	2008-03-06	2013-05-14	Medichem S.A.	Fumaric acid salt of varenicline
WO2009146031A1 (en)	2008-03-31	2009-12-03	University Of South Florida	Methods of treating disease-induced ataxia and non-ataxic imbalance
WO2009143347A2 (en) *	2008-05-22	2009-11-26	Teva Pharmaceutical Industries Ltd.	Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) *	2008-05-26	2009-12-24	Glenmark	Amorphous varenicline tartrate and process for the preparation thereof
WO2009155403A2 (en) *	2008-06-19	2009-12-23	Teva Pharmaceutical Industries Ltd.	Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) *	2008-07-10	2010-01-14	Revital Lifshitz-Liron	Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2334679A1 (en) *	2008-09-01	2011-06-22	Actavis Group PTC EHF	Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof
EP2440187A2 (en)	2009-06-10	2012-04-18	Actavis Group PTC ehf.	Amorphous varenicline tartrate co-precipitates
EP2438054A1 (en)	2009-06-22	2012-04-11	Teva Pharmaceutical Industries Ltd.	Solid states forms of varenicline salts and processes for preparation thereof
CA2791460A1 (en)	2010-03-09	2011-09-15	Actavis Group Ptc Ehf	Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
WO2011140431A1 (en)	2010-05-06	2011-11-10	Teva Pharmaceutical Industries Ltd.	Varenicline salts and crystal forms thereof
US9090623B2 (en)	2012-04-13	2015-07-28	Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd.	Compound JK12A and preparation thereof
KR101663550B1 (ko) *	2014-06-11	2016-10-07	조선대학교산학협력단	주석산을 유효성분으로 포함하는 고혈압 예방 또는 치료용 약학조성물 및 건강기능식품
KR101724301B1 (ko)	2016-11-22	2017-04-10	주식회사 한서켐	바레니클린 살리실산염의 i형 결정 및 그 제조방법
WO2018154395A2 (en)	2018-06-11	2018-08-30	Alvogen Malta Operations (Row) Ltd	Controlled release pharmaceutical composition of varenicline
TW202206078A (zh)	2020-04-28	2022-02-16	美商奧伊斯特普安生物製藥公司	局部投與菸鹼乙醯膽鹼受體促效劑用以抑制冠狀病毒感染
KR20240038022A (ko)	2021-08-20	2024-03-22	비위트 파마슈티컬 컴퍼니 리미티드	니트로사민 불순물, 니트로사민 불순물 생성을 줄일 수 있는 바레니클린 약학 조성물 및 그 제조와 응용
KR20230068877A (ko)	2021-11-11	2023-05-18	주식회사 아울바이오	고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학적 조성물
CN113980020B (zh) *	2021-11-22	2023-05-09	浙江车头制药股份有限公司	一种酒石酸伐尼克兰晶型的制备方法
WO2023275413A2 (en)	2021-12-23	2023-01-05	Medichem, S.A.	Solid pharmaceutical formulations of varenicline
EP4241775A1 (en)	2022-03-11	2023-09-13	Par Pharmaceutical, Inc.	Tablet comprising varenicline and process of preparation thereof
US11602537B2 (en)	2022-03-11	2023-03-14	Par Pharmaceutical, Inc.	Varenicline compound and process of manufacture thereof
WO2023244574A1 (en)	2022-06-14	2023-12-21	Amygdala Neurosciences, Inc.	Aldh-2 inhibitor compounds and methods of use
WO2024095172A1 (en)	2022-11-04	2024-05-10	Pfizer Inc.	Prodrugs of varenicline and compounds containing vulnerable amines
KR20240115109A (ko)	2023-01-18	2024-07-25	주식회사 아울바이오	고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학 조성물
WO2024224270A1 (en)	2023-04-24	2024-10-31	Pfizer Inc.	Varenicline formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3471503A (en)	1967-05-05	1969-10-07	Mcneilab Inc	1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
NZ504482A (en) *	1997-12-31	2003-01-31	Pfizer Prod Inc	Aryl fused azapolycyclic compounds and pharmaceuticals thereof which bind to neuronal nicotinic acetylcholine specific recpetor sites and are useful for modulating cholinergic function
IL137937A0 (en) *	1999-08-27	2001-10-31	Pfizer Prod Inc	A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
CZ20011726A3 (cs) *	2000-05-26	2002-02-13	Pfizer Products Inc.	Způsob reakční krystalizace, který umoľňuje řídit velikost částic

2002
- 2002-04-26 DE DE60205742T patent/DE60205742T2/de not_active Expired - Lifetime
- 2002-04-26 ES ES02722625T patent/ES2246396T3/es not_active Expired - Lifetime
- 2002-04-26 PL PL366551A patent/PL214876B1/pl unknown
- 2002-04-26 KR KR1020037014754A patent/KR100551184B1/ko active IP Right Review Request
- 2002-04-26 EP EP02722625A patent/EP1392307B1/en not_active Expired - Lifetime
- 2002-04-26 BR BR0209605-6A patent/BR0209605A/pt not_active IP Right Cessation
- 2002-04-26 RS YUP-867/03A patent/RS50814B/sr unknown
- 2002-04-26 SI SI200230189T patent/SI1392307T1/sl unknown
- 2002-04-26 UA UA20031110266A patent/UA73422C2/uk unknown
- 2002-04-26 ME MEP-2008-717A patent/ME00466B/me unknown
- 2002-04-26 AU AU2002253482A patent/AU2002253482B2/en not_active Expired
- 2002-04-26 AT AT02722625T patent/ATE302607T1/de active
- 2002-04-26 IL IL15793302A patent/IL157933A0/xx unknown
- 2002-04-26 MX MXPA03010364A patent/MXPA03010364A/es active IP Right Grant
- 2002-04-26 CN CNB028099125A patent/CN100370987C/zh not_active Expired - Lifetime
- 2002-04-26 EA EA200301121A patent/EA005528B1/ru active Protection Beyond IP Right Term
- 2002-04-26 EE EEP200300556A patent/EE05441B1/xx unknown
- 2002-04-26 GE GE5341A patent/GEP20053712B/en unknown
- 2002-04-26 DK DK02722625T patent/DK1392307T3/da active
- 2002-04-26 OA OA1200300289A patent/OA12599A/en unknown
- 2002-04-26 HU HU0304088A patent/HU229867B1/hu unknown
- 2002-04-26 JP JP2002589006A patent/JP3779682B2/ja not_active Expired - Lifetime
- 2002-04-26 CA CA002447405A patent/CA2447405C/en not_active Expired - Lifetime
- 2002-04-26 CZ CZ2003-2916A patent/CZ304763B6/cs not_active IP Right Cessation
- 2002-04-26 NZ NZ528210A patent/NZ528210A/en not_active IP Right Cessation
- 2002-04-26 WO PCT/IB2002/001437 patent/WO2002092089A1/en active IP Right Grant
- 2002-04-26 PT PT02722625T patent/PT1392307E/pt unknown
- 2002-04-26 SK SK1336-2003A patent/SK287170B6/sk not_active IP Right Cessation
- 2002-05-06 DO DO2002000392A patent/DOP2002000392A/es unknown
- 2002-05-06 US US10/139,730 patent/US6890927B2/en not_active Expired - Lifetime
- 2002-05-09 AP APAP/P/2002/002523A patent/AP1473A/en active
- 2002-05-10 GT GT200200084A patent/GT200200084A/es unknown
- 2002-05-10 PE PE2002000391A patent/PE20021065A1/es active IP Right Grant
- 2002-05-10 MY MYPI20021696A patent/MY127807A/en unknown
- 2002-05-13 AR ARP020101734A patent/AR033635A1/es active IP Right Grant
- 2002-05-13 EG EG20020483A patent/EG24228A/xx active
- 2002-05-13 TW TW091109919A patent/TWI262078B/zh not_active IP Right Cessation
- 2002-05-14 PA PA20028545101A patent/PA8545101A1/es unknown
2003
- 2003-07-08 TN TNPCT/IB2002/001437A patent/TNSN03113A1/fr unknown
- 2003-09-15 IL IL157933A patent/IL157933A/en active IP Right Grant
- 2003-09-15 IS IS6957A patent/IS2217B/is unknown
- 2003-09-16 ZA ZA200307235A patent/ZA200307235B/en unknown
- 2003-09-22 CR CR7080A patent/CR7080A/es not_active Application Discontinuation
- 2003-11-10 HR HR20030910A patent/HRP20030910B1/xx not_active IP Right Cessation
- 2003-11-10 MA MA27389A patent/MA27020A1/fr unknown
- 2003-11-11 BG BG108343A patent/BG66408B1/bg unknown
- 2003-11-13 NO NO20035036A patent/NO326148B1/no not_active IP Right Cessation
- 2003-11-14 EC EC2003004849A patent/ECSP034849A/es unknown
- 2003-11-14 EC EC2003004850A patent/ECSP034850A/es unknown
2004
- 2004-07-28 HK HK04105577A patent/HK1062645A1/xx not_active IP Right Cessation
2005
- 2005-02-28 US US11/069,724 patent/US7265119B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
TWI262078B (en)	2006-09-21
DK1392307T3 (da)	2005-11-07
JP3779682B2 (ja)	2006-05-31
NO326148B1 (no)	2008-10-06
DE60205742D1 (de)	2005-09-29
BG108343A (bg)	2004-12-30
SK287170B6 (sk)	2010-02-08
GT200200084A (es)	2003-09-12
EE200300556A (et)	2004-04-15
MY127807A (en)	2006-12-29
NO20035036D0 (no)	2003-11-13
HUP0304088A2 (hu)	2004-04-28
NO20035036L (no)	2003-11-13
CA2447405A1 (en)	2002-11-21
HRP20030910B1 (en)	2011-11-30
EP1392307A1 (en)	2004-03-03
GEP20053712B (en)	2005-12-26
IL157933A0 (en)	2004-03-28
YU86703A (sh)	2006-05-25
CA2447405C (en)	2006-10-17
JP2004533446A (ja)	2004-11-04
EA005528B1 (ru)	2005-04-28
US20050148591A1 (en)	2005-07-07
HUP0304088A3 (en)	2011-11-28
PE20021065A1 (es)	2002-11-21
KR100551184B1 (ko)	2006-02-13
PL214876B1 (pl)	2013-09-30
KR20040010638A (ko)	2004-01-31
BG66408B1 (bg)	2014-01-31
EA200301121A1 (ru)	2004-02-26
DE60205742T2 (de)	2006-05-11
PT1392307E (pt)	2005-11-30
NZ528210A (en)	2005-04-29
SK13362003A3 (en)	2004-11-03
CN1509174A (zh)	2004-06-30
EG24228A (en)	2008-11-10
PA8545101A1 (es)	2003-09-05
HU229867B1 (en)	2014-10-28
ZA200307235B (en)	2004-09-16
TNSN03113A1 (fr)	2005-12-23
ECSP034850A (es)	2003-12-24
DOP2002000392A (es)	2002-11-15
CZ304763B6 (cs)	2014-10-01
CN100370987C (zh)	2008-02-27
US7265119B2 (en)	2007-09-04
AP2002002523A0 (en)	2002-06-30
AU2002253482B2 (en)	2007-09-06
BR0209605A (pt)	2004-03-23
MXPA03010364A (es)	2004-03-16
PL366551A1 (en)	2005-02-07
ECSP034849A (es)	2003-12-24
UA73422C2 (en)	2005-07-15
WO2002092089A1 (en)	2002-11-21
ME00466B (me)	2011-10-10
AP1473A (en)	2005-09-30
MA27020A1 (fr)	2004-12-20
SI1392307T1 (sl)	2005-12-31
US20030166701A1 (en)	2003-09-04
ES2246396T3 (es)	2006-02-16
CZ20032916A3 (cs)	2004-09-15
HRP20030910A2 (en)	2004-02-29
US6890927B2 (en)	2005-05-10
EP1392307B1 (en)	2005-08-24
OA12599A (en)	2006-06-08
AR033635A1 (es)	2003-12-26
RS50814B (sr)	2010-08-31
EE05441B1 (et)	2011-08-15
ATE302607T1 (de)	2005-09-15
IS2217B (is)	2007-03-15
HK1062645A1 (en)	2004-11-19
CR7080A (es)	2006-08-09
IL157933A (en)	2013-07-31

Publication	Publication Date	Title
IS6957A (is)	2003-09-15	Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9,-pentaen og lyfjafræðilegar samsetningar af þeim
NO2023030I1 (no)	2023-08-17	Apixaban and pharmaceutical acceptable salts thereof
NO20033566D0 (no)	2003-08-12	Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer og deres anvendelse som farmasöytiske midler
NO20024175L (no)	2002-10-29	Azetidinderivater, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene
FI20011478A0 (fi)	2001-07-05	Farmaseuttinen koostumus
NO20042739L (no)	2004-07-23	Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
NO20033556L (no)	2003-10-09	Farmasöytiske formuleringer
DE60203581D1 (de)	2005-05-12	Alfa-beta Titanlegierung
NO20035298D0 (no)	2003-11-28	CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
DE60234409D1 (de)	2009-12-31	Säuregenerator, Sulfonsäure, Sulfonsäurederivate und strahlungsempfindliche Zusammensetzung
NO20040125L (no)	2004-01-12	Enterale formuleringer
EE200300416A (et)	2003-12-15	Ravimvorm
NO20042635L (no)	2004-06-23	5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin
DK1417206T3 (da)	2010-08-16	Hidtil ukendte 2H-pyridazin-3-on-derivater, farmaceutiske præparater indeholdende det samme, og en fremgangsmåde til fremstilling af den aktive bestanddel
DE60209929D1 (de)	2006-05-11	Succinate des 5,8,14-triazatetracycloä10.3.1.0 2,11 .0 4,9 ü-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
EE200300589A (et)	2004-02-16	Ravimkoostised
IS6956A (is)	2003-09-15	Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því
NO20040860L (no)	2004-04-22	Farmasoytisk sammensetning som innbefatter lumiracoxib
FI20022128A (fi)	2003-06-06	Farmaseuttinen koostumus
DK1373232T3 (da)	2006-03-27	Fremgangsmåde til fremstilling af N-substituerede 2,6-dialkylmorpholiner
DK1429753T3 (da)	2007-05-14	Farmaceutisk sammensætning omfattende gamma-butyrobetain
EE200300465A (et)	2003-12-15	Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
NO20031369L (no)	2003-05-22	Kalium-kanal interagerende forbindelser, og anvendelser derav
DK1235809T3 (da)	2004-03-15	Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazociner og deres anvendelse som lægemidler
IS7131A (is)	2004-01-29	Nýjar 2,4-díamínóþíasól afleiður